She cited a study from the Institute for Safe Medicine Practices (ISMP) linking Xarelto to 356 adverse events. In 2013, at least 72 deaths in Germany were also linked to Xarelto.
Wise accuses drug-makers of falsely claiming that Xarelto patients do not need routine tests for bleeding and/or blood clots. She also stresses that Xarelto does not have an antidote — unlike warfarin, which can be reversed with a dose of Vitamin K in a bleeding emergency.
The complaint states:
“Due to the flawed formulation of Xarelto, which according to defendants does not require regular blood monitoring or frequent doctor follow-up, raises concerns about the risk of stroke, bleeding, and blood clots if not taken properly or absorbed properly, particularly in patients with poor renal function.”
The wrongful death lawsuit was filed in the Court of Common Pleas in Philadelphia. Wise is seeking compensation for punitive damages, including fraud, wrongful death, consumer law violations, negligence, failure to warn, product liability, unreasonable marketing of a dangerous drug, and breach of warranty.